Traws Pharma (TRAW) stock surged on Tuesday after the clinical-stage biopharmaceutical company revealed results from a rigosertib study as a treatment for patients with RDEB SCC. The results posted by the company include an overall response rate of 80%, with a complete response rate of 50%.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Traws Pharma interim CEO Iain Dukes said, “Rigosertib is available for further development and commercialization, and we are committed to finding an appropriate partner to advance this important medicine to approval.”
TRAW stock was up 57.04% on Tuesday but remains down 84.01% year-to-date. The stock has also fallen 90.44% over the past 12 months.
Is Traws Pharma Stock a Buy, Sell, or Hold?
Wall Street’s coverage of Traws Pharma is lacking. However, TipRanks’ AI analyst, Spark, rates the stock as Underperform (28) with no price target. The rating comes from “significant financial challenges and bearish technical indicators.”
